ArticleiGIE : innovation, investigation and insights2023
Long-term outcomes (≥3 years) after gastric peroral endoscopic myotomy for refractory gastroparesis: a systematic review and meta-analysis.
Article in iGIE : innovation, investigation and insights, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Gastroenterological Society of Australia Position Statement on the Assessment and Management of Idiopathic Gastroparesis.Journal of gastroenterology and hepatology · 2026Guideline
- Gastric peroral endoscopic pyloromyotomy as an effective treatment for symptomatic delayed gastric emptying after Ivor Lewis esophagectomy.iGIE : innovation, investigation and insights · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Gastric peroral endoscopic myotomy (G-POEM) has emerged as a novel management option for patients with refractory gastroparesis. Although G-POEM has shown excellent short-term outcomes, clinical success with symptom resolution in the long-term setting is still being investigated. As such, our aim was to investigate long-term outcomes after G-POEM in patients with gastroparesis. Methods: Multiple databases were searched from inception until March 2023 for studies looking at long-term outcomes (≥3 years) for patients with gastroparesis treated with G-POEM. The primary outcome was clinical success 3 years after G-POEM. Secondary outcomes included changes in Gastroparesis Cardinal Symptom Index score before and 36 months after G-POEM, technical success, adverse events, and length of hospital stay. Quality assessment of studies was performed by using the Qumseya scale. Results: Five studies were included with 560 patients (average age, 47.03 years; 67.8% female) over a mean follow-up of 38.4 months. The pooled rate of clinical success at 36 months was 75% (95% confidence interval [CI], 68.2-80.5; Conclusions: G-POEM has a durable long-term clinical success rate. Further studies are needed to identify patient selection factors that will enhance its clinical success.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.